Health risks of herbal remedies: an update
2004; Wiley; Volume: 76; Issue: 1 Linguagem: Inglês
10.1016/j.clpt.2004.03.005
ISSN1532-6535
Autores Tópico(s)Botanical Studies and Applications
ResumoClinical Pharmacology & TherapeuticsVolume 76, Issue 1 p. 1-17 Perspectives in Clinical Pharmacology Health risks of herbal remedies: An update Peter A. G. M. De Smet PharmD, PhD, Corresponding Author Peter A. G. M. De Smet PharmD, PhD Scientific Institute Dutch Pharmacists, The Hague, The Netherlands Department of Clinical Pharmacy, University Medical Centre St Radboud, Nijmegen, The NetherlandsScientific Institute Dutch Pharmacists, The Hague, The Netherlands. E-mail: [email protected]Search for more papers by this author Peter A. G. M. De Smet PharmD, PhD, Corresponding Author Peter A. G. M. De Smet PharmD, PhD Scientific Institute Dutch Pharmacists, The Hague, The Netherlands Department of Clinical Pharmacy, University Medical Centre St Radboud, Nijmegen, The NetherlandsScientific Institute Dutch Pharmacists, The Hague, The Netherlands. E-mail: [email protected]Search for more papers by this author First published: 01 July 2004 https://doi.org/10.1016/j.clpt.2004.03.005Citations: 16 This review is based in part on a solicited oral presentation for a symposium on herbal medicine as part of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics, Istanbul, Turkey, June 24–28, 2003. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S. and Van Rompay, M., et al. (1998). Trends in alternative medicine use in the United States, 1990–1997: results of a follow–up national survey. JAMA 280: 1569–1575. 2De Smet, P. A. G. M. (1995). Health risks of herbal remedies. Drug Saf 13: 81–93. 3De Smet, P. A. G. M. (1993). An introduction to herbal pharmacoepidemiology. J Ethnopharmacol 38: 197–208. 4Ernst, E. and De Smet, P. A. G. M. (1996). Risks associated with complementary therapies. In: M. N. G. Dukes (Ed). Meyler's side effects of drugs. Elsevier: Amsterdam. p. 1427–1454. 5De Smet, P. A. G. M. (1999). The safety of herbal products. In: W. B. Jonas, and J. S. Levin (Eds). Essentials of complementary and alternative medicine. Lippincott Williams & Wilkins: Philadelphia. p. 108–147. 6De Smet, P. A. G. M. (2002). Herbal remedies. N Engl J Med 347: 2046–2056. 7De Smet, P. A. G. M. (2003). Herbal medicine. N Engl J Med 348: 1500–1501. 8Shekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A. and Suttorp, M., et al. (2003). Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta–analysis. JAMA 289: 1537–1545. 9Szapary, P. O., Wolfe, M. L., Bloedon, L. T., Cucchiara, A. J., DerMarderosian, A. H. and Cirigliano, M. D., et al. (2003). Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290: 765–772. 10Yeh, G. Y., Eisenberg, D. M., Kaptchuk, T. J. and Phillips, R. S. (2003). Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26: 1277–1294. 11Druss, B. G. and Rosenheck, R. A. (1999). Association between use of unconventional therapies and conventional medical services. JAMA 282: 651–656. 12O'Donnell, D. C., Brown, C. M. and Piziak, V. K. (2001). Alternative therapy use and adherence to antihyperlipidemic drugs in a lipid clinic. Am J Health Syst Pharm 58: 1017–1021. 13Brienza, R. S., Stein, M. D. and Fagan, M. J. (2002). Delay in obtaining conventional healthcare by female internal medicine patients who use herbal therapies. J Womens Health Gend Based Med 11: 79–87. 14Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D. and Falloon, J. (2002). The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34: 234–238. 15Janetzky, K. and Morreale, A. P. (1997). Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 54: 692–693. 16Rosado, M. F. (2003). Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology 99: 111. 17Wang, Z., Gorski, J. C., Hamman, M. A., Huang, S. M., Lesko, L. J. and Hall, S. D. (2001). The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70: 317–326. 18Henderson, L., Yue, Q. Y., Bergquist, C., Gerden, B. and Arlett, P. (2002). St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54: 349–356. 19Markowitz, J. S., Donovan, J. L., DeVane, C. L., Taylor, R. M., Ruan, Y. and Wang, J. S., et al. (2003). Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290: 1500–1504. 20De Smet, P. A. G. M. and Smeets, O. S. N. M. (1994). Potential risks of health food products containing yohimbe extracts [letter]. BMJ 309: 958. 21De Smet, P. A. G. M. (1997). Yohimbe alkaloids. In: P. A. G. M. De Smet, K. Keller, R. Hänsel, and R. F. Chandler (Eds). Adverse effects of herbal drugs. Volume 3. Springer–Verlag: Berlin. p. 181–214. 22Weisbord, S. D., Soule, J. B. and Kimmel, P. L. (1997). Poison on line—acute renal failure caused by oil of wormwood purchased through the Internet. N Engl J Med 337: 825–827. 23Hainer, M. I., Tsai, N., Komura, S. T. and Chiu, C. L. (2000). Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 133: 877–880. 24Winickoff, J. P., Houck, C. S., Rothman, E. L. and Bauchner, H. (2000). Verve and Jolt: deadly new Internet drugs. Pediatrics 106: 829–830. 25Bauer, B. A., Elkin, P. L., Erickson, D., Klee, G. G. and Brennan, M. D. (2002). Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol. Mayo Clin Proc 77: 587–590. 26Vanherweghem, J. L., Depierreux, M., Tielemans, C., Abramowicz, D., Dratwa, M. and Jadoul, M., et al. (1993). Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387–391. 27Nortier, J. L., Martinez, M. C., Schmeiser, H. H., Arlt, V. M., Bieler, C. A. and Petein, M., et al. (2000). Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342: 1686–1692. 28Gold, L. S. and Slone, T. H. (2003). Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. N Engl J Med 349: 1576–1577. 29Veronin, M. A. and Ramirez, G. (2000). The validity of health claims on the World Wide Web: a systematic survey of the herbal remedy Opuntia. Am J Health Promot 15: 21–28. 30Martin–Facklam, M., Kostrzewa, M., Schubert, F., Gasse, C. and Haefeli, W. E. (2002). Quality markers of drug information on the Internet: an evaluation of sites about St. John's wort. Am J Med 113: 740–745. 31Bonakdar, R. A. (2002). Herbal cancer cures on the Web: noncompliance with The Dietary Supplement Health and Education Act. Fam Med 34: 522–527. 32Bessell, T. L., Anderson, J. N., Silagy, C. A., Sansom, L. N. and Hiller, J. E. (2003). Surfing, self–medicating and safety: buying non–prescription and complementary medicines via the internet. Qual Saf Health Care 12: 88–92. 33Ashar, B. H., Miller, R. G., Getz, K. J. and Pichard, C. P. (2003). A critical evaluation of Internet marketing of products that contain ephedra. Mayo Clin Proc 78: 944–946. 34Morris, C. A. and Avorn, J. (2003). Internet marketing of herbal products. JAMA 290: 1505–1509. 35Kressmann, S., Muller, W. E. and Blume, H. H. (2002). Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 54: 661–669. 36Westerhoff, K., Kaunzinger, A., Wurglics, M., Dressman, J. and Schubert–Zsilavecz, M. (2002). Biorelevant dissolution testing of St John's wort products. J Pharm Pharmacol 54: 1615–1621. 37Schulz, H. U., Schurer, M., Krumbiegel, G., Wachter, W., Weyhenmeyer, R. and Seidel, G. (1995). The solubility and bioequivalence of silymarin preparations [in German]. Arzneimittelforschung 45: 61–64. 38Garvey, G. J., Hahn, G., Lee, R. V. and Harbison, R. D. (2001). Heavy metal hazards of Asian traditional remedies. Int J Environ Health Res 11: 63–71. 39Ernst, E. and Coon, J. T. (2001). Heavy metals in traditional Chinese medicines: a systematic review. Clin Pharmacol Ther 70: 497–504. 40Ernst, E. (2002). Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol 57: 891–896. 41Weide, R., Engelhart, S., Farber, H., Kaufmann, F., Heymanns, J. and Koppler, H. (2003). Severe lead poisoning due to Ayurvedic indian plant medicine [in German]. Dtsch Med Wochenschr 128: 2418–2420. 42Parab, S., Kulkarni, R. and Thatte, U. (2003). Heavy metals in ‘herbal’ medicines. Indian J Gastroenterol 22: 111–112. 43Krapf, R. (2002). Development of Cushing's syndrome after use of a herbal remedy. Lancet 360: 1884. 44Sovak, M., Seligson, A. L., Konas, M., Hajduch, M., Dolezal, M. and Machala, M., et al. (2002). Herbal composition PC–SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 94: 1275–1281. 45Reynolds, T. (2002). Contamination of PC–SPES remains a mystery. J Natl Cancer Inst 94: 1266–1268. 46Ros, J. J., Pelders, M. G. and De Smet, P. A. G. M. (1999). A case of positive doping associated with a botanical food supplement. Pharm World Sci 21: 44–46. 47Daniels, J., Shaw, D. and Atherton, D. (2002). Use of Wau Wa in dermatitis patients [letter]. Lancet 360: 1025. 48Raman, A. and Jamal, J. (1997). “Herbal” hay fever remedy found to contain conventional drugs. Pharm J 258: 105–106. 49Ernst, E. (2002). Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 23: 136–139. 50Ernst, E. (2002). Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med 252: 107–113. 51Huang, W. F., Wen, K. C. and Hsiao, M. L. (1997). Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 37: 344–350. 52De Smet, P. A. G. M., De Visser, I., Wagenaar, H. W. G. and Andela, M. (1998). Westerse geneesmiddelen vrij verkrijgbaar bij Chinese toko's. Pharm Weekbl 133: 614–618. 53Baba, T., Kataoka, K. and Itakura, M. (1999). Hypoglycemia due to folk medicine. Diabetes Care 22: 1376. 54Ko, R. J. (1998). Adulterants in Asian patent medicines [letter]. N Engl J Med 339: 847. 55Corns, C. and Metcalfe, K. (2002). Risks associated with herbal slimming remedies. J R Soc Health 122: 213–219. 56Wooltorton, E. (2002). Hua Fo tablets tainted with sildenafil-like compound. CMAJ 166: 1568. 57Adachi, M., Saito, H., Kobayashi, H., Horie, Y., Kato, S. and Yoshioka, M., et al. (2003). Hepatic injury in 12 patients taking the herbal weight loss AIDS Chaso or Onshido. Ann Intern Med 139: 488–492. 58Davis, M. P. and Darden, P. M. (2003). Use of complementary and alternative medicine by children in the United States. Arch Pediatr Adolesc Med 157: 393–396. 59Snodgrass, W. R. (2001). Herbal products: risks and benefits of use in children. Curr Ther Res 62: 724–737. 60Ernst, E. (2003). Herbal medicines for children. Clin Pediatr (Phila) 42: 193–196. 61Woolf, A. D. (2003). Herbal remedies and children: do they work? Are they harmful? Pediatrics 112: 240–246. 62 Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. (2003). UK Committee on Safety of Medicines: London Available at: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/ssrioverview_101203.pdf. Accessed December 20, 2003. 63Hübner, W. D. and Kirste, T. (2001). Experience with St John's Wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res 15: 367–370. 64Findling, R. L., McNamara, N. K., O'Riordan, M. A., Reed, M. D., Demeter, C. A. and Branicky, L. A., et al. (2003). An open–label pilot study of St. John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry 42: 908–914. 65Ernst, E. (2003). Serious adverse effects of unconventional therapies for children and adolescents: a systematic review of recent evidence. Eur J Pediatr 162: 72–80. 66Palmer, M. E., Haller, C., McKinney, P. E., Klein–Schwartz, W., Tschirgi, A. and Smolinske, S. C., et al. (2003). Adverse events associated with dietary supplements: an observational study. Lancet 361: 101–106. 67Dergal, J. M., Gold, J. L., Laxer, D. A., Lee, M. S., Binns, M. A. and Lanctot, K. L., et al. (2002). Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 19: 879–886. 68Ness, J., Johnson, D. and Nisly, N. (2003). “Polyherbacy”:: herbal supplements as a form of polypharmacy in older adults. J Gerontol A Biol Sci Med Sci 58: M478. 69Cohen, J. S. (2000). Avoiding adverse reactions. Effective lower–dose drug therapies for older patients. Geriatrics 55: 54–60, 63–64. 70Cohen, J. S. (2002). Do standard doses of frequently prescribed drugs cause preventable adverse effects in women? J Am Med Womens Assoc 57: 105 110–114. 71Onrot, J., Goldberg, M. R., Biaggioni, I., Wiley, R. G., Hollister, A. S. and Robertson, D. (1987). Oral yohimbine in human autonomic failure. Neurology 37: 215–220. 72Jordan, J., Shannon, J. R., Biaggioni, I., Norman, R., Black, B. K. and Robertson, D. (1998). Contrasting actions of pressor agents in severe autonomic failure. Am J Med 105: 116–124. 73Price, L. H., Charney, D. S. and Heninger, G. R. (1984). Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 141: 1267–1268. 74De Smet, P. A. G. M. and Brouwers, J. R. B. J. (1997). Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 32: 427–436. 75Dahl, N. V. (2001). Herbs and supplements in dialysis patients: panacea or poison? Semin Dial 14: 186–192. 76Gallo, M., Koren, G., Smith, M. J. and Boon, H. (2001). The use of herbal medicine in pregnancy and lactation. In: G. Koren (Ed). Maternal–fetal toxicology. A clinician's guide. 3rd ed. Marcel Dekker: New York. p. 569–601. 77Ciganda, C. and Laborde, A. (2003). Herbal infusions used for induced abortion. J Toxicol Clin Toxicol 41: 235–239. 78Blumenthal, M. (1998). The Complete German Commission E monographs—therapeutic guide to herbal medicines. American Botanical Council: Austin (TX). 79Rasenack, R., Muller, C., Kleinschmidt, M., Rasenack, J. and Wiedenfeld, H. (2003). Veno–occlusive disease in a fetus caused by pyrrolizidine alkaloids of food origin. Fetal Diagn Ther 18: 223–225. 80Ernst, E. (2002). Herbal medicinal products during pregnancy: are they safe? BJOG 109: 227–235. 81Chan, L. Y., Chiu, P. Y. and Lau, T. K. (2003). An in–vitro study of ginsenoside Rb1–induced teratogenicity using a whole rat embryo culture model. Hum Reprod 18: 2166–2168. 82 Herbal safety news. (2003). Medicines Control Agency: London. Available at: http://www.mca.gov.uk/ourwork/licensingmeds/herbalmeds/herbalsafety.htm. Accessed at December 20, 2003. 83Kopec, K. (1999). Herbal medications and breastfeeding. J Hum Lact 15: 157–161. 84Westendorf, J. (1992). Pyrrolizidine alkaloids—general discussion. In: P. A. G. M. De Smet, K. Keller, R. Hänsel, R. F. Chandler, (Eds). Adverse effects of herbal drugs. Volume 1. Springer–Verlag; p. 193–205. 85Westendorf, J. (1993). Anthranoid derivatives—general discussion. In: P. A. G. M. De Smet, K. Keller, R. Hänsel, R. F. Chandler, (Eds). Adverse effects of herbal drugs. Volume 2. Springer–Verlag; p. 105–118. 86De Smet, P. A. G. M. (1992). Aristolochia species. In: P. A. G. M. De Smet, K. Keller, R. Hänsel, and R. F. Chandler (Eds). Adverse effects of herbal drugs. Volume 1. Springer–Verlag: Berlin. p. 79–89. 87Skinner, C. M. and Rangasami, J. (2002). Preoperative use of herbal medicines: a patient survey. Br J Anaesth 89: 792–795. 88Ang–Lee, M. K., Moss, J. and Yuan, C. S. (2001). Herbal medicines and perioperative care. JAMA 286: 208–216. 89Psoralea corylifolia fruit in Traditional Chinese Medicines causing severe skin reactions. Current Problems in Pharmacovigilance (Committee on Safety of Medicines of UK Medicines Control Agency) (2001). 27: 12–13. 90Ljunggren, B. (1990). Severe phototoxic burn following celery ingestion. Arch Dermatol 126: 1334–1336. 91Boffa, M. J., Gilmour, E. and Ead, R. D. (1996). Celery soup causing severe phototoxicity during PUVA therapy. Br J Dermatol 135: 334. 92Cairney, S., Maruff, P., Clough, A. R., Collie, A., Currie, J. and Currie, B. J. (2003). Saccade and cognitive impairment associated with kava intoxication. Hum Psychopharmacol 18: 525–533. 93Seppala, T., Linnoila, M. and Mattila, M. J. (1979). Drugs, alcohol and driving. Drugs 17: 389–408. 94Betts, T., Mortiboy, D., Nimmo, J., Knight, R. (1986). A review of research: the effects of psychotropic drugs on actual driving performance. In: J. F. O'Hanlon, J. J. De Gier, (Eds). Drugs and driving. Taylor & Francis: Basingstoke. p. 83–100. 95De Smet, P. A. G. M. (1990). Drugs used in non–orthodox medicine. In: M. N. G. Dukes and L. Beeley (Eds). Side effects of drugs, Annual 14. Elsevier: Amsterdam. p. 429–451. 96Wolschrijn, H., De Gier, J. J. and De Smet, P. A. G. M. (1991). Drugs & driving. A new categorization system for drugs affecting psychomotor performance. Institute for Drugs, Safety and Behavior: Maastricht. 97Möller, M. R. and Krämer, T. (2002). Drugs of abuse monitoring in blood for control of driving under the influence of drugs. Ther Drug Monit 24: 210–221. 98deJong, C. A. J. (1978). Melisana, for your so necessary relaxation? [in Dutch]. Ned Tijdschr Geneeskd 122: 82–83. 99De Smet, P. A. G. M. (1992). Toxicological outlook on the quality assurance of herbal remedies. In: P. A. G. M. De Smet, K. Keller, R. Hänsel, and R. F. Chandler (Eds). Adverse effects of herbal drugs. Volume 1. Springer–Verlag: Berlin. p. 1–72. 100De Smet, P. A. G. M. and D'Arcy, P. F. (1996). Drug interactions with herbal and other non–orthodox remedies. In: P. F. D'Arcy, J. C. McElnay, and P. J. Wellington (Eds). Mechanisms of drug interactions. Springer–Verlag: Berlin. p. 327–352. 101Fugh–Berman, A. (2000). Herb–drug interactions. Lancet 355: 134–138. 102Izzo, A. A. and Ernst, E. (2001). Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61: 2163–2175. 103Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E. and Mitchell, A. A. (2002). Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287: 337–344. 104Dengler, H. J. and Eichelbaum, M. (1977). Polymorphisms and deficient drug metabolism as triggers of toxic reactions [in German]. Arzneimittelforschung 27: 1836–1844. 105Hoffmeyer, S., Burk, O., vonRichter, O., Arnold, H. P., Brockmoller, J. and Johne, A., et al. (2000). Functional polymorphisms of the human multidrug–resistance gene: multiple sequence variations and correlation of one allele with P–glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473–3478. 106Kurata, Y., Ieiri, I., Kimura, M., Morita, T., Irie, S. and Urae, A., et al. (2002). Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P–glycoprotein. Clin Pharmacol Ther 72: 209–219. 107Harris, W. S. and Goodman, R. M. (1968). Hyper–reactivity to atropine in Down's syndrome. N Engl J Med 279: 407–410. 108Garde, J. F., Aston, R., Endler, G. C. and Sison, O. S. (1978). Racial mydriatic response to belladonna premedication. Anesth Analg 57: 572–576. 109Friedl, K. E., Hannan, C. J., Mader, T. H., Patience, T. H. and Schadler, P. W. (1988). Effect of eye color on heart rate response to intramuscular administration of atropine. J Auton Nerv Syst 24: 51–56. 110Meyer, E. C., Sommers, D. K., Schoeman, H. S. and Avenant, J. C. (1990). The effect of autonomic blockers on heart rate: a comparison between two ethnic groups. Br J Clin Pharmacol 29: 254–256. 111Zhou, H. H., Adedoyin, A. and Wood, A. J. (1992). Differing effect of atropine on heart rate in Chinese and white subjects. Clin Pharmacol Ther 52: 120–124. 112Behmanesh, Y. and Abdollahi, M. (2002). Haemolysis after consumption of Viola tricolor. WHO Drug Information 16: 15. 113Lamabadusuriya, S. P. and Jayantha, U. K. (1994). Acalypha indica induced haemolysis in G6PD deficiency. Ceylon Med J 39: 46–47. 114Baker, S. and Thomas, P. S. (1987). Herbal medicine precipitating massive haemolysis. Lancet 1: 1039–1040. 115Li, A. M., Hui, J., Chik, K. W., Li, C. K. and Fok, T. F. (2002). Topical herbal medicine causing haemolysis in glucose-6-phosphate dehydrogenase deficiency. Acta Paediatr 91: 1012. 116Topcu, Z., Chiba, I., Fujieda, M., Shibata, T., Ariyoshi, N. and Yamazaki, H., et al. (2002). CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis 23: 595–598. 117Kao, S. Y., Wu, C. H., Lin, S. C., Yap, S. K., Chang, C. S. and Wong, Y. K., et al. (2002). Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J Oral Pathol Med 31: 505–511. 118Stein, C. M. (2002). Are herbal products dietary supplements or drugs? An important question for public safety. Clin Pharmacol Ther 71: 411–413. 119Marcus, D. M. and Grollman, A. P. (2002). Botanical medicines—the need for new regulations. N Engl J Med 347: 2073–2076. 120 Proposal for a Directive of the European Parliament and of the Council amending the Directive 2001/83/EC as regards traditional herbal medicinal products. (2002). Commission of the European Communities: Brussels. Available at: http://dg3.eudra.org/F2/pharmacos/docs/Doc2002/janv/com2002_1_en.pdf. Accessed April 5, 2002. 121 Amended proposal for a Directive of the European Parliament and of the Council amending the Directive 2001/83/EC as regards traditional herbal medicinal products. (2003). Commission of the European Communities: Brussels. Available at: http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2003/COMM_PDF_COM_2003_0161_F_EN.pdf. Accessed December 20, 2003. 122 Department of Health and Human Services Food and Drug Administration. (2003). Current Good Manufacturing Practice in manufacturing, packing, or holding dietary ingredients and dietary supplements; proposed rule. Fed Regist 68: 12158–12263. 123Burton, B. (2003). Complementary medicines industry in crisis after recall of 1546 products. BMJ 326: 1001. 124Mills, E., Singh, R., Ross, C., Ernst, E. and Ray, J. G. (2003). Sale of kava extract in some health food stores [letter]. CMAJ 169: 1158–1159. 125Marcus, D. M. and Grollman, A. P. (2003). Ephedra–free is not danger–free. Science 301: 1669–1671. 126Pellati, F., Benvenuti, S., Melegari, M. and Firenzuoli, F. (2002). Determination of adrenergic agonists from extracts and herbal products of Citrus aurantium L. var. amara by LC. J Pharm Biomed Anal 29: 1113–1119. 127Calapai, C., Firenzuoli, F., Saitta, A., Squadrito, F., Arlotta, M. R. and Costantino, G. et al. (1999). Antiobesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat: a preliminary report. Fitoterapia 70: 586–592. 128Lawyer, C. H. (2001). Herbal medications in the Physician's Desk Reference [letter]. N Engl J Med 344: 1255. 129Haller, C. A., Anderson, I. B., Kim, S. Y. and Blanc, P. D. (2002). An evaluation of selected herbal reference texts and comparison to published reports of adverse herbal events. Adverse Drug React Toxicol Rev 21: 143–150. 130Sweet, B. V., Gay, W. E., Leady, M. A. and Stumpf, J. L. (2003). Usefulness of herbal and dietary supplement references. Ann Pharmacother 37: 494–499. 131Ko, R. J. (1999). Causes, epidemiology, and clinical evaluation of suspected herbal poisoning. J Toxicol Clin Toxicol 37: 697–708. 132Bensoussan, A., Myers, S. P., Drew, A. K., Whyte, I. M. and Dawson, A. H. (2002). Development of a Chinese herbal medicine toxicology database. J Toxicol Clin Toxicol 40: 159–167. 133Kawasaki, Y., Goda, Y. and Yoshihira, K. (1992). The mutagenic constituents of Rubia tinctorum. Chem Pharm Bull (Tokyo) 40: 1504–1509. 134Lindquist M. (2003). Seeing and observing in international pharmacovigilance. Achievements and prospects in worldwide drug safety [PhD thesis]. Uppsala Monitoring Centre: Uppsala. 135Berry, D. C., Raynor, D. K., Knapp, P. and Bersellini, E. (2003). Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 26: 1–11. 136De Smet, P. A. G. M. (1997). An introduction to herbal pharmacovigilance. In: P. A. G. M. De Smet, K. Keller, R. Hänsel, and R. F. Chandler (Eds). Adverse effects of herbal drugs. Volume 3. Springer–Verlag: Berlin. p. 1–13. 137Farah, M. H., Edwards, R., Lindquist, M., Leon, C. and Shaw, D. (2000). International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf 9: 105–112. 138Leiper, J. M. and Lawson, D. H. (1985). Why do doctors not report adverse drug reactions? Neth J Med 28: 546–550. 139Barnes, J., Mills, S. Y., Abbot, N. C., Willoughby, M. and Ernst, E. (1998). Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face–to–face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 45: 496–500. 140Haller, C. A. and Benowitz, N. L. (2000). Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343: 1833–1838. 141Samenuk, D., Link, M. S., Homoud, M. K., Contreras, R., Theoharides, T. C. and Wang, P. J., et al. (2002). Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 77: 12–16. 142Dulloo, A. G., Seydoux, J. and Girardier, L. (1994). Paraxanthine (metabolite of caffeine) mimics caffeine's interaction with sympathetic control of thermogenesis. Am J Physiol 267: E801–804. 143Morgenstern, L. B., Viscoli, C. M., Kernan, W. N., Brass, L. M., Broderick, J. P. and Feldmann, E., et al. (2003). Use of Ephedra–containing products and risk for hemorrhagic stroke. Neurology 60: 132–135. 144Haller, C. A., Jacob, P. III and Benowitz, N. L. (2002). Pharmacology of ephedra alkaloids and caffeine after single–dose dietary supplement use. Clin Pharmacol Ther 71: 421–432. 145Burnakis, T. G. (2003). Comment: usefulness of herbal and dietary supplement references. Ann Pharmacother 37: 1346. 146Hollister, A. S. and Kearns, G. L. (2003). American Society for Clinical Pharmacology and Therapeutics position statement on the public health risks of ephedra. Clin Pharmacol Ther 74: 403–405. Citing Literature Volume76, Issue1July 2004Pages 1-17 ReferencesRelatedInformation
Referência(s)